Cargando…
Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
BACKGROUND: Discontinuation of Nucleos(t)ide analogs (NAs) remains one of the most controversial topics in the management of hepatitis B-related liver cirrhosis. However, clinical outcomes after NAs discontinuation have not been studied. AIM: The aim of this systematic review is to evaluate existing...
Autores principales: | Yao, Yuhao, Zhang, Jiaxin, Li, Xiaoke, Zao, Xiaobin, Cao, Xu, Chen, Guang, Ye, Yong'an |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670108/ https://www.ncbi.nlm.nih.gov/pubmed/36407996 http://dx.doi.org/10.3389/fpubh.2022.1037527 |
Ejemplares similares
-
Identification of pseudo-immune tolerance for chronic hepatitis B patients: Development and validation of a non-invasive prediction model
por: Li, Shuo, et al.
Publicado: (2023) -
Uncovering the Pharmacological Mechanisms of Gexia-Zhuyu Formula (GXZY) in Treating Liver Cirrhosis by an Integrative Pharmacology Strategy
por: Cao, Xu, et al.
Publicado: (2022) -
The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification
por: Cao, Xu, et al.
Publicado: (2021) -
Exploring the mechanism of JiGuCao capsule formula on treating hepatitis B virus infection via network pharmacology analysis and in vivo/vitro experiment verification
por: Cao, Xu, et al.
Publicado: (2023) -
Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma
por: Cao, Xu, et al.
Publicado: (2022)